Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) and Pacira BioSciences (NASDAQ:PCRX – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Insider & Institutional Ownership
97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Ultragenyx Pharmaceutical and Pacira BioSciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ultragenyx Pharmaceutical | 1 | 1 | 16 | 0 | 2.83 |
| Pacira BioSciences | 1 | 2 | 3 | 0 | 2.33 |
Risk & Volatility
Ultragenyx Pharmaceutical has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
Earnings & Valuation
This table compares Ultragenyx Pharmaceutical and Pacira BioSciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ultragenyx Pharmaceutical | $560.23 million | 4.17 | -$569.18 million | ($5.94) | -4.08 |
| Pacira BioSciences | $700.97 million | 1.27 | -$99.56 million | $0.45 | 45.93 |
Pacira BioSciences has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Ultragenyx Pharmaceutical and Pacira BioSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ultragenyx Pharmaceutical | -91.95% | -414.17% | -43.66% |
| Pacira BioSciences | 2.99% | 12.82% | 6.57% |
Summary
Pacira BioSciences beats Ultragenyx Pharmaceutical on 10 of the 14 factors compared between the two stocks.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
About Pacira BioSciences
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
